These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 20302552)

  • 21. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ; Gums JG
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M
    QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
    McFarlane SI
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1363-71. PubMed ID: 19900019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Weber MA
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.
    Chrysant SG
    Clin Ther; 2008; 30 Pt 2():2181-90. PubMed ID: 19281913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future.
    Weber M
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2 Suppl 2():S12-6. PubMed ID: 11881103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V
    J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?
    Volpe M; Ruilope LM; McInnes GT; Waeber B; Weber MA
    J Hum Hypertens; 2005 May; 19(5):331-9. PubMed ID: 15744333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospects for the prevention of stroke.
    Dahlöf B
    J Hypertens Suppl; 2006 Apr; 24(2):S3-9. PubMed ID: 16601558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies.
    Hao G; Wang Z; Guo R; Chen Z; Wang X; Zhang L; Li W
    BMC Cardiovasc Disord; 2014 Oct; 14():148. PubMed ID: 25344747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?
    Pourdjabbar A; Lapointe N; Rouleau JL
    Can J Cardiol; 2002 May; 18 Suppl A():7A-14A. PubMed ID: 12045788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.